Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
Join ActionIf you are a Telix Pharmaceuticals investor who suffered a loss and would like to learn more, you can provide your information below:
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Lead Plaintiff Deadline: January 9, 2026
📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
💻 Or submit your information below to learn about your rights.